Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30075334 | 0.98 | LIG1 (0.41) | LIG1ALDH1A1ALOX15SRCALOX5 | |
| SCHEMBL30647012 | 0.89 | SRC (0.51) | LIG1ALDH1A1ALOX15SRCALOX5 | |
| SCHEMBL1520555 | 0.89 | SRC (0.51) | LIG1ALDH1A1ALOX15SRCALOX5 | |
| SCHEMBL749668 | 0.88 | SRC (0.47) | LIG1ALDH1A1ALOX15SRCGFER | |
| SCHEMBL9667622 | 0.87 | ALDH1A1 (0.45) | ALDH1A1ALOX15SRCPDPK1PARP1 | |
| SCHEMBL3384116 | 0.84 | SRC (0.39) | ALDH1A1SRCPDPK1PARP1PARP10 | |
| SCHEMBL6246982 | 0.84 | SRC (0.39) | ALDH1A1SRCPDPK1PARP1PARP10 | |
| SCHEMBL3384120 | 0.84 | AURKA (0.50) | ALDH1A1ALOX15SRCPDPK1PARP1 | |
| SCHEMBL10544590 | 0.83 | AKR1C3 (0.46) | ALDH1A1PDPK1PARP1PARP10PARP11 | |
| SCHEMBL6246983 | 0.81 | SRC (0.36) | SRCPDPK1PARP1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109734703-B | Preparation method of indoline-7-carboxylic ester compound | 中国科学院兰州化学物理研究所 | 2021-06-08 | — | — | CN | claimed |
| WO-2025045835-A1 | PESTICIDALLY ACTIVE OXOINDOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| EP-3670515-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230025807-A1 | CD38 INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2023-01-26 | — | — | US | disclosed |
| WO-2023275357-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-05 | — | — | WO | disclosed |
| EP-4112631-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-04 | — | — | EP | disclosed |
| CN-109734703-B | Preparation method of indoline-7-carboxylic ester compound | 中国科学院兰州化学物理研究所 | 2021-06-08 | — | — | CN | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3388436-B1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-1994008965-A1 | N-ALKYLPIPERIDINYL-4-METHYL CARBOXYLIC ESTERS/AMIDES OF CONDENSED RING SYSTEMS AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-28 | — | — | WO | disclosed |
| EP-0360079-B1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-02-02 | — | — | EP | disclosed |
| US-5248679-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-28 | — | — | US | disclosed |
| CN-1022187-C | Method for preparation of tricyclic compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1993-09-22 | — | — | CN | disclosed |
| US-5155101-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| US-4981847-A | Tricyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-01 | — | — | US | disclosed |
| CN-1040981-A | Tricyclic compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1990-04-04 | — | — | CN | disclosed |
| EP-0360079-A1 | Tricyclic compounds, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-03-28 | — | — | EP | disclosed |
| EP-0239927-A1 | Cyclic carbamates | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-10-07 | — | — | EP | disclosed |
| US-3941806-A | ANTIINFLAMMATORY | A. H. ROBINS COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025807-A1 | CD38 INHIBITORS | CD38, GLS, IDH2 | LIG1 1693/4885ALDH1A1 140/4885ALOX15 1110/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | LIG1 1780/4885ALDH1A1 4309/4885ALOX15 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.